17 August 2020>: Animal Study
Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK SignalingDong-shan Zhu 1ABCDEF , Jing-yao Dong 1BCF , Yao-yao Xu 2BCD , Xin-tong Zhang 2BCD , Shi-bo Fu 2ACEFG* , Wei Liu 1ACEFG*
Med Sci Monit 2020; 26:e927106
Figure 3 Omipalisib inhibited the proliferation of Esophageal squamous cell carcinoma (ESCC) cells. (A) Representative data of 3 independent experiments in cell viability of ESCC exposed to a series of concentrations of omipalisib for 72 hours. (B, C) Representative image of clone formation assay for ESCC cells treated with omipalisib for 72 hours. Clone numbers were calculated. (D) ESCC cells were treated with a series of omipalisib and cisplatin concentrations for 72 hours, and cell viability was measured by MTT assay. (* P<0.05, ** P<0.01, *** P<0.001).